Streetbeat News

Analyst Ratings

BLK

BTCUSD

IYK

LYV

NYCB

On CNBC's 'Halftime Report Final Trades,' Stephen Weiss recommended Bitcoin as it traded above $37,000 following news that BlackRock plans to create an ETF focused on ETH. Jenny Harrington highlighted New York Community Bancorp's 7.5% dividend yield and its better-than-expected Q3 earnings. Josh Brown mentioned Live Nation Entertainment, which has seen consolidation since July and reported strong Q3 revenue. Shannon Saccocia chose iShares US Consumer Staples ETF. NYCB, LYV, and IYK shares all saw gains in the last session.

Portfolio Pulse from Lisa Levin

November 13, 2023 | 2:14 pm

CZR

Morgan Stanley analyst Stephen Grambling has maintained an Equal-Weight rating on Caesars Entertainment (NASDAQ:CZR) but has reduced the price target from $50 to $48.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:14 pm

AKYA

Stephens & Co. analyst Mason Carrico maintains an Overweight rating on Akoya Biosciences (NASDAQ:AKYA) but reduces the price target from $14 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:13 pm

CRSP

Morgan Stanley analyst Terence Flynn has maintained an Underweight rating on CRISPR Therapeutics (NASDAQ:CRSP) and reduced the price target from $43 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:13 pm

VYX

Charles Nabhan, an analyst at Stephens & Co., has maintained an Overweight rating on NCR Voyix (NYSE:VYX) but reduced the price target from $35 to $19.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:11 pm

EXPD

Morgan Stanley analyst Ravi Shanker has maintained an Underweight rating on Expeditors International (NASDAQ:EXPD) and reduced the price target from $85 to $84.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:11 pm

FATE

Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Fate Therapeutics (NASDAQ:FATE) but has reduced the price target from $5 to $3.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:09 pm

FHTX

Morgan Stanley analyst Vikram Purohit has maintained an Equal-Weight rating on Foghorn Therapeutics (NASDAQ:FHTX) but reduced the price target from $10 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:08 pm

HOLX

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Hologic (NASDAQ:HOLX) but reduced the price target from $86 to $82.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:07 pm

WMT

Stephens & Co. analyst Ben Bienvenu has maintained an Overweight rating on Walmart (NYSE:WMT) and increased the price target from $185 to $190.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:06 pm